Sector News

WuXi to build dedicated vaccine facility, but who’s the client?

May 21, 2019
Life sciences

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a contract that should produce $150 million a year for 20 years. It just didn’t identify the client.

The Chinese CDMO Monday announced the letter of intent, saying WuXi Vaccines will build a vaccine manufacturing facility that will be able to handle substance and drug product manufacturing and will include quality control labs. It said it has estimated the value of the 20-year manufacturing contract at more than $3 billion.

“Vaccine CDMO is one of the next growth areas for WuXi Biologics,” WuXi Biologics CEO Chris Chen said in a statement.

While WuXi didn’t identify the partner, it offered a couple clues. It said the site will manufacture 100% of the global market of one the partner’s vaccine products, suggesting the vaccines might be intended for use outside China. Most Chinese vaccine makers only produce for the country.

Also, when WuXi Vaccines was formed last year as a joint venture between WuXi Biologics and veterinary vaccine maker Shanghai Hile Bio-Technology, WuXi said in a securities filing the venture was being formed to primarily make cancer vaccines.

Reports in the China media earlier this year said WuXi was in talks with three vaccine developers to make their products in China. But Chen at the time suggested the company might be making a play for the country’s vaccination market after regulatory reactions to scandals by Chinese makers limited their production.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend